Comparative Claims At RSNA Trade Show Draw FDA Ire For Bracco Diagnostics
This article was originally published in The Gray Sheet
Executive SummaryBracco Diagnostics says it has resolved promotional violations raised in an untitled FDA letter stating that the firm made comparative claims for its MultiHance MRI contrast imaging agent, an investigational new drug, during a November 2000 trade show in Chicago.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.